DMRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Damora Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$19.27+0.83 (+4.50%)
Close on Oct 19, 2026
- Market cap
- $1.18B
- P/E (TTM)
- 4.8
- Dividend yield
- 0.00%
Damora Therapeutics statistics
Financials through Jun 30, 2026, price-based ratios appear once a share price is available, median of Pharmaceutical Preparations companies for comparison
Income (trailing twelve months)
| Measure | Damora Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$270.66M | -$21.40M |
| Pretax Income | -$262.49M | -$14.34M |
| Net Income | -$262.83M | -$22.46M |
| EBITDA | -$270.66M | -$16.91M |
Returns
| Measure | Damora Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -99.7% | -53.2% |
| Return on Assets (ROA) | -94.3% | -40.9% |
| Return on Capital Employed (ROCE) | -52.4% | -38.1% |
Balance sheet
| Measure | Damora Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $540.52M | $61.43M |
| Net Cash (Debt) | $540.52M | $15.35M |
| Net Cash Per Share | $8.76 | $0.66 |
| Equity (Book Value) | $516.06M | $49.09M |
| Book Value Per Share | $8.36 | $1.37 |
| Tangible Book Value | $516.06M | $23.52M |
| Working Capital | $516.04M | $76.81M |
Financial position
| Measure | Damora Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 19.73 | 3.34 |
| Quick Ratio | 19.62 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Damora Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$44.52M | -$12.35M |
Efficiency
| Measure | Damora Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$37.55M | -$703.34K |
| Employee Count | 7 | 74 |
Dividends and yields
| Measure | Damora Therapeutics | Industry median |
|---|---|---|
| Dividend Per Share | $0.00 | $0.83 |
| Years of Dividend Growth | 0 | 0 |
Shares
| Measure | Damora Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 61,735,500 | 58,127,000 |
| Shares Change (YoY) | 1824.6% | 10.9% |
| Shares Change (QoQ) | 2.37% | 0.54% |
| Float | 50,856,200 | 49,136,700 |
| Shares Held by Insiders | 17.6% | 11.6% |
| Shares Held by Institutions | 105.1% | 59.4% |
Taxes
| Measure | Damora Therapeutics | Industry median |
|---|---|---|
| Income Tax | $341.00K | $79.87K |
Scores
| Measure | Damora Therapeutics | Industry median |
|---|---|---|
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Damora Therapeutics's SEC filings. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.